Received Date: January 31, 2018; Accepted Date: April 23, 2018; Published Date: April 30, 2018
Citation: Katherine LP, Rogerio A, Nataki CD, Jessica S, Arielle G et al. (2018) Do Fertility Outcomes Differ in an Underinsured Urban Predominantly Hispanic population? A Single Center Experience. J Reproductive Endocrinol & Infert. Vol.3 No.1:4
Racial disparities persist in many aspects of modern healthcare, including the diagnosis and treatment of patients with infertility. These measures are particularly understudied in Hispanic women. The objective of this study is to compare fertility outcomes of an underinsured, largely Hispanic population to outcomes from national cohorts. Capsule: Conception rates following controlled ovarian stimulation in underinsured minority populations are poor providers should be proactive in encouraging patients to pursue in vitro fertilization when possible.
Hispanic; socioeconomic disparities; access to care; infertility; controlled ovarian stimulation
AMH: Anti-Müllerian Hormone; AFC: Antral Follicle Count; ART: Assisted Reproductive Technology; BMI: Body Mass Index; CWRC: Center for Women’s Reproductive Care; CUMC: Columbia University Medical Center; COS: Controlled Ovarian Stimulation; ET: Embryo transfer; IUI: Intrauterine Insemination; IVF: In vitro fertilization; NSFG: National Survey of Family Growth; NEJM: New England Journal of Medicine; PCOS: Polycystic ovary Syndrome; REI: Reproductive Endocrinology and Infertility; RMN: Reproductive Medicine Network; TIC: Timed Inter Course
Infertility affects all racial, ethnic and socio-economic groups. According to the 2013 National Survey of Family Growth (NSFG), 12% of women in the United Sates experienced infertility in 2002, an increase from 8.4% of women in 1982 . Delayed childbearing undoubtedly contributes to the increasing incidence of infertility. Paralleling this trend, assisted reproductive technology (ART) has evolved considerably over this period. ART involves all procedures in which oocytes, sperm, or embryos are manipulated in a laboratory setting to achieve reproduction. Since the first ART birth reported in 1978 , many couples are now able to conceive and achieve desired family size because of advancements in this field.
Multiple studies have shown that only a fraction of the population has access to ART or other infertility treatments, leading to disparities in infertility prevalence by race and ethnicity [3-5]. NSFG reports (2010) demonstrate that while 15% of non-Hispanic white women sought infertility treatments to achieve pregnancy, only 8.0% of non-Hispanic black women and 7.6% of Hispanic women did so [4,5]. Furthermore, of those women with access to infertility services, the duration of infertility and treatment outcomes differed in minority groups compared to the rest of the population [4,5]. Using 2010 Society for Assisted Reproductive Technology reports, Fujimoto et al. highlighted that live birth rates following ART were lower in minority groups versus white women: 10% less for Asian women, 13% less for Hispanic women, and 38% less for black women . The reasons for these differences remain unclear. In response to these findings, the Center for Disease Control and Prevention released the National Public Health Action Plan for the Detection, Prevention, and Management of Infertility, aspiring to eliminate disparities in access to high-quality infertility services . Similarly, the Ethics Committee of the American Society for Reproductive Medicine recognizes the creation of a family as a basic human right and encourages all ART providers to strive to lessen barriers to infertility care .
Multiple factors may contribute to disparities in access to infertility treatment and differences in treatment outcomes. Disparities in education, especially health education, may limit understanding of their medical conditions and infertility diagnosis and treatment options . Disparities in access and use of preventative care services contribute to disparities in general medical health and comorbid conditions, as well as delayed diagnosis and referral to specialists, including infertility providers . Consequently fertility treatments begin at later age, with higher number of comorbid conditions, and lower overall prognosis. Furthermore, disparities in conditions known to cause infertility may account for differences in treatment outcomes when infertility services are accessible. For example, the incidence of tubal disease, Fragile X gene mutation, and obesity varies between women of different races, with minorities being disproportionately affected [4,11-15]. Similarly, Shuler et al. showed significant variation in infertility diagnoses according to ethnicity: Hispanic women have increased incidence of tubal factor infertility compared to non-Hispanic white women . For many patients, the cost of infertility services is insurmountable, thus preventing adequate access to and use of care. According to 2016 estimates, the cost of one cycle of in vitro fertilization (IVF) may exceed 50% of the average American individual's annual disposable income if these services are not covered by insurance [17-19]. Consequently, cost limits the availability of infertility services to patients of lower socioeconomic status across all races and ethnicities.
The Columbia University Medical Center (CUMC) Reproductive Endocrinology and Infertility (REI) Clinic at Audubon Practice provides unique access to fertility treatments for uninsured and underinsured patients at an income-based, fee per appointment cost. Patients are self-referred or referred by ambulatory care providers within the New York Presbyterian Hospital network as well as providers from the greater tri-state area. The clinic is staffed by CUMC REI fellows and Obstetrics and Gynecology residents, under the supervision of a CUMC board-certified REI attending physician. The clinic provides complete infertility evaluation, including hormonal assays, ultrasonography, and saline infused sonohysterogram. Patients are referred for a hysterosalpingogram and semen analysis, as well as genetic testing and counseling, urology evaluation and gynecologic surgery, when indicated. In-person or telephone translator services are available for non-English speaking patients. A dedicated nurse with expertise in endocrinology and infertility coordinates patient care and facilitates communication between patients and physicians. The clinic offers ovulation induction and controlled ovarian stimulation (COS) with clomiphene citrate, letrozole, and gonadotropins. Cycles are monitored with serial ultrasounds and ovulation is timed with ovulation predictor kits or Ovidrel®. Conception is attempted with timed intercourse (TIC) or intrauterine insemination (IUI), including donor sperm IUI. IUIs are performed at the CUMC Center for Women’s Reproductive Care (CWRC) with the assistance of the CWRC andrology team and under the supervision of a CWRC attending physician. Access to ART services is also possible for patients who desire or require these treatments. IVF approval is based on the qualifying criteria of the New York State Department of Health Infertility Demonstration Program .
The REI clinic at Audubon Practice attracts a wide range of patients from New York City and the surrounding region, as well as internationally. Based in Washington Heights, New York, a large proportion of patients are of Hispanic ethnicity, providing a unique opportunity to evaluate infertility outcomes in this population. The purpose of this study was to assess treatment outcomes of patients with polycystic ovary syndrome (PCOS) or unexplained infertility in this underinsured, majority Hispanic population. We hypothesized that with adequate access to infertility services, these women would experience conception rates and pregnancy outcomes similar to those previously reported for national cohorts of women with PCOS or unexplained infertility.
This retrospective study included women undergoing COS cycles at the CUMC REI Clinic at Audubon Practice between January 2012 and December 2016. A total of 239 patients collectively underwent 858 COS cycles between January 2012 and December 2016. Of these cycles, 449 (52.3%) were conducted in Hispanic patients. Based on diagnoses following infertility evaluation, two groups of women were identified: women with PCOS (n=38 women, 100 cycles) and women with unexplained infertility (n=47 women, 175 cycles). Women with alternative infertility diagnoses or multiple diagnoses in combination with PCOS or unexplained infertility were excluded from our analysis. Cancelled cycles and cycles without known cycle outcomes were excluded from analysis (Figure 1). The diagnosis of PCOS was based on Rotterdam Criteria , with laboratory exclusion of alternative diagnoses. The diagnosis of unexplained infertility was made following negative male and female infertility testing, which included normal ovarian reserve testing (as defined by antral follicle count (AFC), early follicular phase follicle stimulating hormone (FSH) and estradiol levels, and anti-Müllerian hormone levels), normal thyroid stimulating hormone and prolactin testing, patent fallopian tubes on hysterosalpingogram, normal uterine cavity assessment on saline infused sonohysterogram, and normal semen assessment according to 2010 World Health Organization guidelines .
Demographic information and baseline infertility testing information were collected, including age (years), body mass index (BMI, kg/m2), race, ethnicity, anti-Müllerian hormone (AMH) level (ng/mL), baseline FSH level (mIU/mL), and AFC. Conception with TIC versus IUI was noted. Data points were obtained through abstraction from existing patient electronic records. The demographics of the Audubon Practice patients as well as PCOS and unexplained infertility cohorts are presented in Table 1. Cycle outcomes, including conception rate, biochemical pregnancy rate, miscarriage rate, and ongoing pregnancy rate were recorded. The Columbia University Medical Center Institutional Review Board approved this study, IRB #AAAR0502.
Table 1 Audubon Practice Demographic Data.
|Audubon Practice ALL+ n= 858||Audubon Practice PCOS* n=100||Audubon Practice Unexplained Infertility* n=175|
|Age, years||34.5 ± 6.0||29.6 ± 6.2||33.9 ± 3.7|
|BMI, kg/m2||27.1 ± 5.32||28.6 ± 5.6||25.7 ± 4.6|
|Race||Asian||34 (4.0%)||3 (3%)||8 (4.6%)|
|White||131 (15.3%)||13 (13.0%)||16 (9.1%)|
|Missing/Unknown||635 (80.2%)||84 (84%)||150 (85.7%)|
|Ethnicity||Hispanic||449 (52.3%)||59 (59%)||103 (58.9%)|
|Not Hispanic||131 (15.3%)||3 (3%)||19 (10.9%)|
|Missing/Unknown||278 (32.4%)||38 (38%)||53 (30.2%)|
|AMH, ng/mL||2.1 ± 2.88||6.2 ± 4.3||2.5 ± 1.5|
|FSH, mIU/mL||6.8 ± 3.74||5.4 ± 1.8||6.8 ± 2.3|
|AFC, follicle #||16.7 ± 9.5||28.0 ± 5.6||16.3 ± 7.4|
|Ovulation Method||OPK||414 (48.3%)||36 (36%)||106 (60.6%)|
|Ovidrel||243 (28.3%)||55 (55%)||52 (29.5%)|
|Missing/Unknown||201 (23.4%)||9 (9%)||19 (10.9%)|
|Conception Method||TIC||501 (58.4%)||82 (82%)||124 (70.9%)|
|IUI||184 (21.4%)||17 (17%)||50 (28.6%)|
|dsIUI||59 (6.9%)||0||1 (0.6%)|
|Missing/Unknown||114 (13.3%)||1 (1%)||0|
Note BMI: Body Mass Index; NH/PI: Native Hawaiian/Pacific Islander; AMH : Anti-Müllerian Hormone; FSH: Follicle Stimulating Hormone; AFC: Antral Follicle Count; OPK: Ovulation Predictor Kit; TIC: Timed Inter Course; IUI: Intrauterine Insemination; dsIUI: Donor Sperm Intrauterine Insemination data are represented as mean ± standard deviation or n (% total). + Data includes patients will all infertility diagnoses treated with COS at the CUMC REI clinic at audubon practice between 2012 and 2016. * All cycles included (clomiphene, letrozole, gonadotropin, natural cycles).
Controlled ovarian stimulation and intrauterine insemination
After spontaneous menstruation or induced withdrawal bleeding, patients initiated clomiphene citrate (50 mg, 100 mg, or 150 mg) or letrozole (2.5 mg, 5 mg, or 7.5 mg) between cycle days 2 to 5 for 5 days. Medication choice and medication dosage were determined by patient age, ovarian reserve testing, prior cycle outcomes, and provider or patient preference. Gonadotropin and natural cycles were excluded from analysis due to low number. Follicle growth was assessed with ultrasound 1 week after medication initiation and subsequently every two days as determined by follicle growth and patient availability. Cycles were cancelled if inadequate follicle growth was appreciated (with subsequent follow up ultrasounds), or if an inappropriately high number of follicles were identified. Ovulation was detected with use of ovulation predictor kits, or induced with Ovidrel® when follicle size reached a mean diameter of 22 mm and ovulation had not yet occurred. The infertility nurse provided patients with in-person training on ovulation predictor kit use. Following ovulation, couples initiated timed intercourse, or underwent IUI with partner or anonymous donor sperm. Timed intercourse was instructed to occur the evening of positive morning ovulation kit and the following evening. If ovulation was induced with Ovidrel®, couples were instructed to have intercourse the subsequent two evenings after administration. IUI was timed to the morning following a positive evening ovulation predictor kit or two mornings following Ovidrel® injection. Although IUI was advised for all couples with unexplained infertility, this treatment was not always possible due to patient financial constraints.
In vitro fertilization
Patients with PCOS or unexplained infertility who underwent IVF during the study period were identified. The cycle characteristics and fertility outcomes of these patients were evaluated.
The primary outcome was rate of conception. Conception was defined as a positive serum human chorionic gonadotropin level. Secondary outcomes included rate of biochemical pregnancy, miscarriage and ongoing pregnancy. Biochemical pregnancy was defined as conception with subsequent decline in human chorionic gonadotropin without ultrasound evidence of pregnancy (gestational sac with yolk sac). Miscarriage was defined as conception with ultrasound evidence of pregnancy and subsequent pregnancy loss. Ongoing pregnancy was defined as conception with ultrasound evidence of pregnancy and subsequent discharge from fertility practice.
CUMC PCOS patient outcomes
Of 858 total COS cycles, 146 (17.0%) cycles were conducted in patients with a diagnosis of PCOS and 100 cycles were included in the analysis: 45 (45%) with clomiphene citrate, 47 (47%) with letrozole, 7 (7%) with gonadotropins and 1 (1%) using no ovulation induction medications (Table 2). Fifty-nine percent of PCOS patients identified as Hispanic. Conception was attempted with TIC in 83 (83%) patients and with IUI in 17 (17%) patients. Conception was higher for PCOS patients following letrozole (19.1%) compared to clomiphene citrate (13.3%) (Table 3). During the study period, 10 patients with PCOS pursued IVF, collectively undergoing 14 IVF cycles. These cycles resulted in 5 fresh embryo transfers and 4 frozen embryo transfers, with 6 (66.7%) transfers resulting in conception, and 4 (44.4%) ongoing pregnancies.
Table 2 Baseline characteristics of Columbia University Medical Center (CUMC) and Reproductive Medicine Network (RMN) cohorts with polycystic ovary syndrome (PCOS) and unexplained infertility.
|CUMC OVERALL+ n=100||CUMC Clomiphene n=45 (45%)||RMN Clomiphene n=376||p-value||CUMC Letrozole n=47 (47%)||RMN Letrozole n=374||p-value|
|Age (years)||29.6 ± 6.2||29.2 ± 4.8||28.8 ± 4.0||0.536a||29.2 ± 7.4||28.9 ± 4.5||0.693a|
|BMI (kg/m2)||28.6 ± 5.6||28.1 ± 5.6||35.1 ± 9.0||<0.001a||29.1 ± 5.6||35.2 ± 9.5||<0.001a|
|Hispanic||59 (59%)||30 (66.7%)||68 (18.1%)||<0.001b||24 (51.1%)||60 (16%)||<0.001b|
|Conception Method||TIC||83 (83%)||45 (100%)||376 (100%)||36 (76.6%)||374 (100%)||<0.001b|
|IUI||17 (17%)||0||0||11 (23.4%)||0||<0.001b|
|UNEXPLAINED INFERTILITY PATIENTS|
|CUMC OVERALL+ n=175||CUMC Clomiphene n=110 (62.9%)||RMN Clomiphene n=300||p-value||CUMC Letrozole n=59 (33.7%)||RMN Letrozole n=299||p-value|
|Age (years)||33.9 ± 3.7||33.3 ± 3.8||32.0 ± 4.6||0.008a||34.8 ± 3.4||32.2 ± 4.3||<0.001a|
|BMI (kg/m2)||25.7 ± 4.6||25.9 ± 4.5||26.7 ± 6.4||0.229a||25.2 ± 4.9||27.3 ± 6.5||0.019a|
|Hispanic||103 (58.9%)||67 (60.9%)||30 (10.0%)||<0.001b||33 (55.9%)||35 (11.7%)||<0.001b|
|Conception Method||TIC||124 (70.9%)||80 (72.7%)||0||<0.001b||42 (71.2%)||0||<0.001b|
|IUI||50 (28.6%)||29 (26.4%)||300 (100%)||<0.001b||17 (28.8%)||299 (100%)||<0.001b|
|dsIUI||1 (0.6%)||1 (0.9%)||0||0.268b||0||0|
Note: BMI: Body Mass Index; TIC: Timed InterCourse; IUI: Intrauterine Insemination; dsIUI: Donor Sperm Intrauterine Insemination Data are represented as mean ± standard deviation or n (% total). + All cycles included (clomiphene, letrozole, gonadotropin, natural cycles) a Student’s t-test b Two-tailed Fisher’s exact test
Table 3 Controlled ovarian stimulation (COS) cycle outcomes of Columbia University Medical Center (CUMC) and Reproductive Medicine Network in the polycystic ovary.
|CUMC OVERALL+ n=100||CUMC Clomiphene n=45 (45%)||RMN Clomiphene n=376||p-value||CUMC Letrozole n=47 (47%)||RMN Letrozole n=374||p-value|
|Conception||16 (16.0%)||6 (13.3%)||103 (27.4%)||0.047a||9 (19.1%)||154 (41.2%)||0.004a|
|Pregnancy Outcomes||Biochemical||1 (11.0%)||0||18 (9.7%)||0.587a||1 (11.1%)||29 (18.8%)||1.000a|
|Ectopic||1 (11.0%)||1 (16.7%)||4 (3.9%)||0.251a||0||4 (2.6%)||1.000a|
|Miscarriage||3 (18.8%)||0||30 (29.1%)||0.185a||2 (22.2%)||49 (31.8%)||0.721a|
|Ongoing||11 (68.8%)||5 (83.3%)||81 (78.6%)||1.000a||6 (66.7%)||117 (76.0%)||0.690a|
|UNEXPLAINED INFERTILITY PATIENTS|
|CUMC OVERALL+ n=175||CUMC Clomiphene n= 110 (61.2%)||RMN Clomiphene n=300||p-value||CUMC Letrozole n=59 (33.7%)||RMN Letrozole n=299||p-value|
|Conception||7 (4.0%)||5 (4.5%)||106 (35.3%)||<0.001a||0||85 (28.4%)||<0.001a|
|Pregnancy Outcomes||Biochemical||1 (14.3%)||1 (20.0%)||14 (4.7%)||0.224a||0||13 (4.3%)||1.000a|
|Ectopic||0||0||5 (1.7%)||1.000a||0||5 (1.7%)||1.000a|
|Miscarriage||0||0||10 (3.3%)||1.000a||0||8 (7.7%)||1.000a|
|Ongoing||6 (85.7%)||4 (80.0%)||85 (28.3%)||1.000a||0||67 (22.4%)||1.000a|
Syndrome (PCOS) and unexplained infertility cohorts. Data are represented as n (% total). + All cycles included (clomiphene, letrozole, gonadotropin, natural cycles) a Two-tailed Fisher’s exact test
CUMC unexplained infertility patient outcomes
Of 858 total COS cycles, 183 (21.3%) cycles were conducted in patients with a diagnosis of unexplained infertility and 175 cycles were included for analysis: 110 (62.9%) with clomiphene citrate, 59 (33.7%) with letrozole, 4 (2.3%) with gonadotropins, and 2 (1.1%) using no COS medications. Fifty-nine percent of patients with unexplained infertility identified as Hispanic. Conception was attempted with TIC in 124 (70.9%) patients, with IUI in 50 (28.6%) patients, and with dsIUI in 1 (0.6%) patient. Conception was higher for unexplained infertility patients following clomiphene citrate (4.5%) compared to letrozole (0%). When analysis was limited to patients under age 35 receiving clomiphene citrate COS (n=66), conception rate remained low (n=3, 4.5%). When analysis was limited to patients undergoing clomiphene citrate COS with IUI or dsIUI (n=30), conception rate still remained low (n=2, 6.7%). During the study period, 5 patients with unexplained infertility pursued IVF, collectively undergoing 5 IVF cycles. These cycles resulted in 4 fresh embryo transfers, with 4 (100%) transfers resulting in conception, and 2 (50%) ongoing pregnancies.
Critical analysis and reporting of current fertility outcomes in minority populations is a vital first step in order to address disparities in fertility health and infertility treatment. By contributing to the available knowledge on these populations, health care professionals, insurance providers and policy makers will have the data required to initiate and implement meaningful practice change. This study reports on the infertility treatment outcomes of an urban, predominantly Hispanic population, a minority group that is critically underrepresented in medical literature. We found that conception rates in this underinsured minority population were poor and were much lower than rates in multicenter trials using COS.
The PCOS patient cohort from the Reproductive Medicine Network (RMN) described in the 2014 New England Journal of Medicine (NEJM) trial  evaluated a predominantly (77- 80%). Caucasian population that achieved a 27.4% conception rate following clomiphene citrate and a 41.2% conception rate following letrozole. Similarly, the unexplained infertility cohort from the Reproductive Medicine Network (RMN) described in the 2015 New England Journal of Medicine trial  evaluated a predominantly (79-81%) Caucasian population that achieved a 35.3% conception rate following clomiphene citrate and a 28.4% conception rate following letrozole. While there are many methodological differences between the RMN trials and our current study, the conception rates experienced by our predominantly Hispanic PCOS and unexplained infertility cohorts were far lower than expected, given these previously published cohorts.
In the RMN PCOS trial, TIC was used for all conception attempts, while in our patient population TIC was used 82% of the time. In the RMN unexplained infertility trial, IUI was used for all conception attempts, while in our patient population, only 29.1% of patients attempted conception with IUI or dsIUI. Even when TIC cycles were excluded, conception rates remained poor. Patients in our unexplained infertility cohort were on average older than patients in the RMN cohort. When analysis was limited to patients under 35 years, outcomes remained poor, though the very low number of patients with conception limits this extrapolation. Interestingly, although our patient cohort demonstrated lower BMI than the RMN cohorts, often associated with improved conception rates, this did not portend favorable outcomes for our patients.
Reviewing our clinical experiences, we wondered if our practice patterns might have contributed to poorer outcomes. For example, our older patients with unexplained infertility did more COS cycles than would be recommend in standard practice. The Group Health Incorporated insurance provides ART coverage following 3 unsuccessful IUI if women are over 35 years of age. Our patients over the age of 35 years with unexplained infertility underwent a mean of 3.9 COS cycles during the study period. Numerous exceptions also occurred. For example, one patient underwent 11 COS cycles with clomiphene citrate, letrozole and gonadotropins before accruing enough resources to pursue IVF. Unfortunately, the vast majority of our patients ultimately never pursued IVF, or were lost to follow up, if no conception occurred after multiple cycles of COS. These additional cycles with poor prognosis may have altered our overall conception rates. It is well known that socioeconomic disparities contribute to limited access and use of infertility treatments, especially costly ART services [5,25-30]. Our patients were similarly limited by the expense of ART – while many patients desired or required IVF to achieve optimal fertility, few patients were ultimately able to pursue ART due to financial constraints. These restrictions are likely attributable to the limited access to care that affects all low socioeconomic populations.
Multiple other factors may account for the differences in outcomes between our underinsured minority population and the RMN cohorts. For example, while access to care limits healthcare for minorities living in remote locations [10,11]. Even a location within the metropolitan of New York City experienced similar disparities in access to care. Patients miss appointments due to lengthy commutes on public transportation, delays and cancellations in public transportation, uncompromising employers who limit work absences, and inadequate childcare coverage for appointments. We estimate that as many as one third of our patients were unable to comply with optimal cycle management – wither attending multiple appointments for improved follicle monitoring, using Ovidrel® instead of ovulation predictor kits, or undergoing IUI instead of timed intercourse – due to their socioeconomic status. Thus, patients attended fewer medical appointments, resulting in fewer opportunities for preventative intervention of general medical conditions, delayed or suboptimal treatment of existing medical conditions, and delayed referral to subspecialist providers. In addition to inadequate access to general medical care and fertility treatments, disparities in health literacy may also contribute to differences in treatment outcomes  Lower education and health literacy may limit these patients’ comprehension of their medical condition, its overall health impact, and available treatment options. This limited comprehension impacts treatment compliance and may negatively influence treatment outcome. Language differences between providers and patients, even with the use of certified medical translation services, may compound these differences .
When our patients pursued IVF, conception and ongoing pregnancy rates were high and similar to national averages: 66.7% of PCOS patients and 100% of patients with unexplained infertility achieved conception following embryo transfer, though our low numbers limit generalizability. While the improved outcomes with IVF are expected compared to alternative fertility treatment methods, additional improved success may reflect closer ultrasound and serum monitoring that occurs during the IVF process, in addition to higher patient motivation and compliance with treatment and follow up. Herndon et al.  described a novel low-cost IVF program aiming to bridge the access and financial gaps in ART services for low resource populations. The group not only demonstrated feasibility of low-cost ART through four low-stimulation protocols, but also achieved promising pregnancy outcomes, citing a 29% cumulative live birth rate . Thus, fertility providers treating underserved populations should be proactive in encouraging patients to pursue IVF when possible, and may consider cost-effective ART protocols to achieve pregnancy in low-resource populations. Moreover, healthcare networks and insurance providers will benefit from further evaluating the efficacy and cost-savings of alternative ART regimens for different socioeconomic populations.
The authors acknowledge there are limitations to this study. First, the inherent limitations as a retrospective review and the small sample size may limit the wider application of these study findings. We also note that a significant amount of racial demographic information for our patient cohort is either missing or unknown. We believe this is related to inadequate demographic surveys in which patients of Hispanic descent consider “Hispanic” to be their identifying race over “White,” “Black,” or “Other.” In preparation for the 2020 Census, the United States Census Bureau is considering combining race and ethnicity divisions under the following categories: White, Hispanic/Latino/Spanish, Black/African American, Asian, American Indian/Alaskan Native, Middle Eastern/North African, Native Hawaiian/Other Pacific Islander, Other Race/Ethnicity/Origin [32,33]. This is supported by the fact that more patients identified as either “Hispanic” or “Not Hispanic” than a specific race. Additionally, the inclusion of patients undergoing greater than 3 COS cycles may be lowering the overall conception rate. If these patients were able to access IVF sooner, conception rates for the COS cohort may have been modestly higher.
This study highlights discrepancies in access to and use of care such as IVF in low-income, low-resource settings and potentially identifies ethnic differences in response to COS. It is our hope that these findings may prompt larger epidemiologic and prospective investigation to clarify ethnic differences in fertility care and outcomes. Providers should be cognizant of the limitations of COS in underserved populations. When possible, providers should consider encouraging these patients to proceed with IVF, or to conserve resources to ultimately pursue IVF, if pregnancy has not been achieved within a predetermined number of COS cycles.
Low-cost ART services offer a promising adjunct to traditional ART treatment that may bridge gaps in access and use of fertility care in minority populations.
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : March 25, 2019